Single Nucleotide Polymorphism 309 Affects Murin-Double-Minute 2 Protein Expression But Not Glioma Tumorigenesis

Access this Article

Search this Article

Author(s)

    • NISHI Toru
    • Department of Neurosurgery, Saiseikai Kumamoto Hospital
    • NAKAMURA Hideo
    • Department of Neurosurgery, Kumamoto University School of Medicine
    • MAKINO Keishi
    • Department of Neurosurgery, Kumamoto University School of Medicine

Abstract

Murin-double-minute 2 (MDM2) is an important negative regulator of the p53 tumor suppressor, and affects the p53 protein level and transcriptional activity. The genotype of the single nucleotide polymorphism in the promoter region of MDM2 (single nucleotide polymorphism [SNP] 309) is associated with the MDM2 protein expression level and the onset age of several types of cancer. The SNP309 genotype was investigated in 254 Japanese patients with glioma and 50 healthy subjects. The genotype frequency of SNP309 was T/T homozygous in 62 patients (24%), T/G heterozygous in 126 (50%), and G/G homozygous in 66 (26%) of the glioma patients, and was similar in the healthy subjects. The G/G ratio was higher in our Japanese subjects than in Western populations. Immunohistochemical study of glioma tissues showed that the G/G genotype was associated with higher expression of MDM2 protein compared to the T/T genotype, suggesting that SNP309 attenuates MDM2 protein expression in vivo. However, no association was found between the SNP309 genotype and the histological grade of glioma, age at disease onset, or p53 gene mutation rate. In our study population, SNP309 affected MDM2 protein level, but had no significant involvement in glioma tumorigenesis.<br>

Journal

  • Neurologia medico-chirurgica

    Neurologia medico-chirurgica 47(5), 203-208, 2007-05-15

    The Japan Neurosurgical Society

References:  17

Codes

  • NII Article ID (NAID)
    110006274447
  • NII NACSIS-CAT ID (NCID)
    AN00358613
  • Text Lang
    ENG
  • Article Type
    ART
  • ISSN
    04708105
  • Data Source
    CJP  NII-ELS  J-STAGE 
Page Top